CD28 antibody (APC)

Catalog No. ABIN7456385

This anti-CD28 antibody is a Golden Syrian Hamster Monoclonal antibody detecting CD28 in FACS. Suitable for Mouse.

Quick Overview for CD28 antibody (APC) (ABIN7456385)

Target: CD28

Reactivity: Mouse

Host: Golden Syrian Hamster

Clonality: Monoclonal

Conjugate: This CD28 antibody is conjugated to APC

Application: Flow Cytometry (FACS)

Clone: 37-51

Product Details anti-CD28 Antibody (APC)

Isotype: IgG

Application Details

Application Notes: Check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use. We suggest each investigator should titrate the reagent to obtain optimal results [The recommended concentration is 0.1-1 μg/10^6 cells in 100 μL volume].

Comment:

Matching Isotype Control: APC Syrian Hamster IgG Isotype Control

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: PBS with 0.05 % Proclin300, 1 % BSA

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2~8°C and protected from prolonged exposure to light. Do not freeze.

Target Details for CD28

Target: CD28

Alternative Name: CD28

Background: T-cell-specific surface glycoprotein CD28,Cd28,CD28,CD28 is a 44 kD glycoprotein, also known as Tp44 or T44. It is a member of the Ig superfamily, expressed on thymocytes, most peripheral T cells, and NK cells. In association with CD80 (B7-1) and CD86 (B7-2), CD28 acts as the second signal for T and NK cell activation and proliferation. The 37.51 antibody has been reported to augment in vitro T cell proliferation and cytokine production, and promote CTL development.

Gene ID: 12487

UniProt: P31041

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response